Parse Biosciences
Parse Biosciences is seeking a Manufacturing Associate to contribute to the expansion of its manufacturing capabilities by performing manual and automated production processes for product manufacturing and kitting. The role requires a detail-oriented individual to execute and improve manufacturing processes while adhering to safety and quality standards in a laboratory environment. This position involves collaborating with support functions and participating in continuous improvement initiatives to enhance operational efficiency.
Headquarters
Seattle, Washington, United States
Company Size
51-200 employees
Founded
2018
Parse Biosciences develops Evercode™, a scalable single‑cell sequencing platform and workflow designed to remove the limitations of microfluidics‑based methods. Their combinatorial barcoding–based kits and protocols enable flexible, high‑throughput single‑cell and single‑nucleus experiments across a wide range of scales, improving accessibility and cost‑efficiency for labs. Parse supplies reagents, library‑preparation workflows, and analysis support compatible with standard sequencers so researchers can run studies from small experiments to very large screens without specialized instrumentation.
Seattle’s Parse Biosciences to be acquired by Qiagen for $225M
Nov 6, 2025
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
3 weeks ago
Press Release Service: Parse Biosciences Invalidates Scale Biosciences (now 10x Genomics) Patent
Oct 9, 2025
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Parse Biosciences.
32% above the average for this role
QIAGEN acquires Parse Biosciences Inc for US$225m
Nov 5, 2025